Cocktails, tablets, capsules, and individual purified formulations of protease inhibitors and phosphatase inhibitors designed to protect proteins from degradation during cell lysis and extraction.
Les produits de certains de nos fournisseurs ne s'affichent pas dans les résultats de la recherche filtrée. Veuillez
supprimer tous les filtres
pour voir ces produits.
Y-27632A, CAS 146986-50-7, is a cell-permeable, reversible, inhibitor of Rho kinases (Ki = 140 nM for p160ROCK). Enhances survival & cloning efficiency of ESC without affecting their pluripotency.
The Aurora Kinase Inhibitor VI, ZM447439, also referenced under CAS 331771-20-1, controls the biological activity of Aurora Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
A cell-permeable, orally bioavailable, blood-brain barrier-permeant MTIC [5-(3-methyltriazen-1-yl-)-imidazole-4-carboxamide] prodrug whose in vivo DNA alkylating activity is employed in anticancer ther
Epoxomicin, Synthetic, CAS 134381-21-8, is a potent, specific, and irreversible inhibitor of chymotrypsin-like, trypsin-like, and peptidyl-glutamyl peptide hydrolyzing activities of the proteasome.
The InSolution™ AMPK Inhibitor, Compound C·2HCl, also referenced under CAS 866405-64-3, controls the biological activity of AMPK. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
SU5402, CAS 215543-92-3, is a cell-permeable, reversible, and ATP-competitive inhibitor of the tyrosine kinase activity of FGFR1 (IC50 = 10 to 20 μM in the presence of 1 mM ATP).
AMPK Inhibitor, Compound C, CAS 866405-64-3, is a cell-permeable compound that inhibits KDR/VEGFR2, ALK2/BMPR-I, and AMPK kinase activities (IC50 = 25.1, 148, and 234.6 nM, respectively).
A cell-permeable compound that increases intralysosomal pH and impairs autophagic degradation process. Suppresses proliferation of human dermal fibroblasts (IC50 = 30 μM).
A potent, reversible, and selective inhibitor of Cdks that exhibits about 10-fold greater efficacy towards p34-cdk1 and p33-cdk2 and 20-fold greater efficacy towards p33-cdk5 relative to Olomoucine.